These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1081356)

  • 21. [Neuroleukemia in mice with leukemia L1210 treated with methotrexate].
    Petrov SA
    Gematol Transfuziol; 1989 Nov; 34(11):46-50. PubMed ID: 2612863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of "early" thymidine/inosine protection as an adjunct to methotrexate therapy.
    Eleff M; Franks PE; Wampler GL; Collins JM; Goldman ID
    Cancer Treat Rep; 1985; 69(7-8):867-74. PubMed ID: 2410122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of folate analogue transport inward in L1210 cells during methotrexate therapy of leukemic mice: evidence of the nature of the effect, possible host mediation, and pharmacokinetic significance.
    Sirotnak FM; Poser RE; Barrueco JR
    Cancer Res; 1987 Oct; 47(20):5334-9. PubMed ID: 3498533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modification of in vivo methotrexate antitumor effect in L1210 leukemia by induced impairment of purine salvage.
    Browman GP; Csullog GW
    Biochem Pharmacol; 1981 Apr; 30(8):869-74. PubMed ID: 7195709
    [No Abstract]   [Full Text] [Related]  

  • 25. Identical efficacy of methotrexate regimens with N5-methyltetrahydrofolate rescue or with leucovorin rescue for treatment of L1210 murine leukemia.
    Nixon PF; Wilson L
    Cancer Treat Rep; 1983 Jan; 67(1):59-62. PubMed ID: 6604578
    [No Abstract]   [Full Text] [Related]  

  • 26. Enhancement of 6-thioguanine cytotoxic activity with methotrexate.
    Armstrong RD; Vera R; Snyder P; Cadman E
    Biochem Biophys Res Commun; 1982 Nov; 109(2):595-601. PubMed ID: 7181934
    [No Abstract]   [Full Text] [Related]  

  • 27. Biochemical and pharmacokinetic effects of leucovorin after high-dose methotrexate in a murine leukemia model.
    Sirotnak FM; Donsbach RC; Moccio DM; Dorick DM
    Cancer Res; 1976 Dec; 36(12):4679-86. PubMed ID: 1087182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of tests of chemotherapeutic agents involving repeated drug treatment.
    Ullman NS; Jacquez JA
    Biometrics; 1973 Dec; 29(4):677-93. PubMed ID: 4785233
    [No Abstract]   [Full Text] [Related]  

  • 29. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.
    Widemann BC; Balis FM; Murphy RF; Sorensen JM; Montello MJ; O'Brien M; Adamson PC
    J Clin Oncol; 1997 May; 15(5):2125-34. PubMed ID: 9164227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth rate and cell kill.
    Hryniuk WM; Bertino JR
    Ann N Y Acad Sci; 1971 Nov; 186():330-42. PubMed ID: 5289425
    [No Abstract]   [Full Text] [Related]  

  • 31. Evaluation of ribonucleoside and deoxyribonucleoside triphosphate pools in cultured leukemia cells during exposure to methotrexate or methotrexate plus thymidine.
    Kinahan JJ; Otten M; Grindey GB
    Cancer Res; 1979 Sep; 39(9):3531-9. PubMed ID: 476679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of methotrexate on the leukemic cell cycle in mouse ascitic leukemia L1210].
    Goncharova SA; Frankfurt OS
    Tsitologiia; 1975 Sep; 17(9):1051-6. PubMed ID: 1166521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of priming dose schedules in methotrexate treatment of mouse leukemia L1210.
    Straus MJ; Mantel N; Goldin A
    Cancer Res; 1971 Oct; 31(10):1429-33. PubMed ID: 5095131
    [No Abstract]   [Full Text] [Related]  

  • 34. The use of leucovorin orally in normal and leukemic L1210 mice to prevent the toxicity and gastrointestinal lesions caused by high doses of methotrexate.
    Sandberg JS; Goldin A
    Cancer Res; 1970 May; 30(5):1276-80. PubMed ID: 5310586
    [No Abstract]   [Full Text] [Related]  

  • 35. The return of antimetabolite sensitivity in methotrexate- and 6-mercaptopurine-resistant L1210 murine leukemia by the process of adaptive selection.
    Wallerstein H; Slater LM; Eng B; Calman N
    Cancer Res; 1972 Oct; 32(10):2235-40. PubMed ID: 5080766
    [No Abstract]   [Full Text] [Related]  

  • 36. Radiosensitivity of drug-resistant L1210 leukemia.
    Johnson RE
    Cancer Res; 1967 Feb; 27(2):251-4. PubMed ID: 6018559
    [No Abstract]   [Full Text] [Related]  

  • 37. "Rescue" techniques in cancer chemotherapy: use of leucovorin and other rescue agents after methotrexate treatment.
    Bertino JR
    Semin Oncol; 1977 Jun; 4(2):203-16. PubMed ID: 301662
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of solid L1210 murine tumors with local hyperthermia and temperature-sensitive liposomes containing methotrexate.
    Weinstein JN; Magin RL; Cysyk RL; Zaharko DS
    Cancer Res; 1980 May; 40(5):1388-95. PubMed ID: 6892792
    [No Abstract]   [Full Text] [Related]  

  • 39. [Chemotherapy of L1210 leukemia: comparison of 7 drugs given either continuously for 20 days, or in a single massive dose, early or late].
    Mathé G; Schwarzenberg L; Hayat M; Schneider M
    Rev Fr Etud Clin Biol; 1968 Dec; 13(10):951-60. PubMed ID: 5306738
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunosuppressive activity of methotrexate and arabinosyl cytosine in mice bearing L1210 leukaemia.
    Baldini L; Brambilla G; Cavanna M; Parodi S
    Br J Pharmacol; 1968 Nov; 34(3):674P-676P. PubMed ID: 5726804
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.